- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05755828
Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
Prospective, Multicenter, Open, One-arm Clinical Study of Safety and Efficacy of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At present, the incidence of malignant hematological diseases represented by leukemia, lymphoma and multiple myeloma is increasing year by year, ranking in the top ten of tumor incidence and mortality, which greatly endangers people's health and social development . B-cell non-Hodgkin's lymphoma (NHL) is a common aggressive malignant lymphoma. Poor response of some patients to traditional first-line chemotherapy is one of the major problems facing this disease. As a result, researchers are using emerging tools such as high-throughput sequencing to further understand the nature of the disease, refine the classification of the disease, and on this basis develop personalized treatments to improve the prognosis of the disease.
Lymphoma has a complex immunosuppressive microenvironment that may prevent CAR T from achieving sustained precision tumor killing. As a revolutionary immunotherapy strategy, CAR-T therapy is currently faced with some bottleneck problems such as post-treatment relapse (including antigen loss relapse and antigen positive relapse), CAR-T consumption, off-target effect and so on.
At present, autologous stem cell transplantation still plays a pivotal role in high-risk B-NHL. But at the same time, autologous stem cell transplantation is also faced with the age of patients, the influence of minimal residual disease (MRD) status before transplantation, chemotherapy dependence sensitivity, post-transplantation recurrence, post-transplantation granulosis infection and other problems.
In this study, we explored the efficacy and safety of autologous stem cell transplantation combined with Anti-CD19 CAR-T cells in the treatment of B-cell NHL in patients with B-NHL who achieved partial response (PR) in the interim assessment after 3-4 courses of first-line therapy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Wei Sang, M.D., Ph.D.
- Phone Number: 13645207648
- Email: xyfylbl515@xzhmu.edu.cn
Study Locations
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221002
- Recruiting
- The Affiliated Hospital of Xuzhou Medical University
-
Contact:
- Wei Sang, M.D., Ph.D.
- Phone Number: 13645207648
- Email: xyfylbl515@xzhmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients or their legal guardians voluntarily participate and sign the informed consent;
- Male or female patients aged 18-70 years (including 18 and 70 years);
- CD19+ B-NH was confirmed by pathology and histology, and the patient achieved a partial response (PR) by interim assessment after 3-4 courses of first-line chemotherapy;
- B-cell non-Hodgkin lymphoma mainly includes the following two types:
(1) Diffuse large B-cell lymphoma (DLBCL); Mantle cell lymphoma (MCL); 5. Measurable or evaluable lesions; 6. The patient's main tissues and organs function well:
- Liver function: ALT/AST < 3 times the upper limit of normal (ULN) and total bilirubin ≤34.2μmol/L;
- Renal function: creatinine < 220μmol/L;
- Lung function: indoor oxygen saturation ≥95%;
- Cardiac function: left ventricular ejection fraction (LVEF) ≥40%. 7. The patient's peripheral shallow venous blood flow is smooth, which can meet the needs of intravenous infusion; 8. Patients with ECOG score ≤2 and expected survival time ≥3 months.
Exclusion Criteria:
- Women who are pregnant (urine/blood pregnancy test positive) or breastfeeding;
- Men or women who have planned to become pregnant within the last 1 year;
- The patients were not guaranteed to take effective contraceptive measures (condoms or contraceptives, etc.) within 1 year after enrollment;
- Patients had uncontrollable infectious diseases within 4 weeks prior to enrollment;
- Active hepatitis B/C virus;
- Hiv-infected patients;
- Suffering from a serious autoimmune disease or immunodeficiency disease;
- The patient is allergic to antibodies, cytokines and other macromolecular biological drugs;
- The patient had participated in other clinical trials within 6 weeks prior to enrollment;
- Systemic use of hormones within 4 weeks prior to enrollment (except for inhaled hormones);
- Suffers from mental illness;
- The patient has substance abuse/addiction;
- According to the researchers' judgment, the patient had other conditions that were not suitable for inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASCT+CAR-T Cell Infusion
CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d*5d).
BEAM pretreatment was performed.
Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was > 2*106/kg.
On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation.
The patients were given constant intravenous drip/push infusion for 30 minutes.
|
CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d*5d).
BEAM pretreatment was performed.
Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was > 2*106/kg.
On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation.
The patients were given constant intravenous drip/push infusion for 30 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response rate
Time Frame: From 3 months to 1 year.
|
Proportion of enrolled patients who achieved complete response after treatment
|
From 3 months to 1 year.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: From 3 months to 1 year.
|
The time interval between patient infusion of CAR-T and death from any cause or the end of follow-up.
|
From 3 months to 1 year.
|
Progression-free survival
Time Frame: From 3 months to 1 year.
|
The time between treatment and observation of disease progression or death from any cause.
|
From 3 months to 1 year.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XYFY2022-KL480-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B-cell Lymphoma
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Nathan DenlingerBristol-Myers SquibbRecruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditionsUnited States
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Australia, Taiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Massachusetts General HospitalVarian Medical SystemsRecruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
University of ChicagoMerck Sharp & Dohme LLCRecruitingLymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
Curocell Inc.RecruitingHigh-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell LymphomaKorea, Republic of
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditionsUnited States
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
Clinical Trials on ASCT+CAR-T Cell Infusion
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruitingAcute T-lymphoblastic Leukemia | Acute T-lymphoblastic LymphomaChina
-
Memorial Sloan Kettering Cancer CenterWithdrawnLymphoma | Lymphoma, B-Cell | LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...RecruitingBreast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the LeptomeningesUnited States
-
Wuhan Union Hospital, ChinaGuangzhou Bio-gene Technology Co., LtdNot yet recruitingSystemic Lupus Erythematosus
-
CARsgen Therapeutics Co., Ltd.Active, not recruitingMultiple MyelomaUnited States, Canada
-
920th Hospital of Joint Logistics Support Force...RecruitingB-Cell Leukemia | B-Cell Lymphoma | B-cell TumorsChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalRecruitingCAR | Malignant TumorsChina
-
The First Affiliated Hospital of Soochow UniversityThe First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaboratorsRecruitingPlatelet Transfusion Refractoriness | Acute Leukemia in RemissionChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalRecruiting
-
Beijing GoBroad HospitalRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic LeukemiaChina